CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
June 8, 2021—Diazyme launched its FDA 510(k)–exempt Beta-Hydroxybutyrate Assay for the quantitative determination of beta-hydroxybutyrate. BHB serves as a guide for monitoring the progress of insulin therapy for diabetic ketoacidosis and for patients presenting to the emergency room with documented hypoglycemia, acidosis, alcohol ingestion, or an unexplained increase in the anion gap.
Pages: 1 2